Daily inhibition of postprandial hyperglycaemia with JTT-608, a novel oral antidiabetic agent, ameliorates pancreatic function in neonatally streptozotocin-treated rats

Diabetes, Obesity and Metabolism

Volumn 7, Issue 5, 2005, Pages 517-524

  Ohta, Takeshi ^a   Sasase, T ^a   Miyajima, K ^a   Matsui, K ^a   Matsushita, M ^a   Furukawa, N ^a   Yonemori, F ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Antidiabetic agent; Cataract; Insulin secretion; JTT 608; Liquid meal; Postprandial hyperglycaemia; Streptozotocin treated rat

Indexed keywords

4 (4 METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; 4 (METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; BUTYRIC ACID DERIVATIVE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES CONTROL; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOREACTIVITY; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MALE; MEAL; MOTOR NERVE CONDUCTION; NONHUMAN; PANCREAS FUNCTION; POSTPRANDIAL STATE; RAT; STREPTOZOCIN DIABETES;

EID: 23844446790     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2004.00419.x     Document Type: Article

References (32)

1. Ginsberg BJ, Mazze R. Clinical consequences of the Diabetes Control and Complications Trial. N J Med 1994; 91 (4): 221-224.
2. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 (2): 103-117.
3. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998; Suppl. 3: C35-C38.
4. Schchiri M, Kishikawa H, Ohkubo Y et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl. 2): B21-B29.
5. Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl. 4): S128-S132.
6. Lehmann R. The significance of postprandial glycemia. Schweiz Rundsch Med Prax 2001; 90: 345-348.
7. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46 (Suppl.): M9-M16.
8. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26 (3): 511-522.
9. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. Br Med J 1988; 296: 949-950.
10. Kawai K, Suzuki S, Murayama Y, Watanabe Y, Yamashita K. Comparison of B-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats. Diabetes Res Clin Pract 1991; 12: 163-172.
11. Ohta T, Furukawa N, Yonemori F, Wakitani K. JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol 1999; 367: 91-99.
12. Ohta T, Furukawa N, Komuro G, Yonemori F, Wakitani K. JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats. Br J Pharmacol 1999; 126: 1674-1680.
13. Furukawa N, Ohta T, Noguchi T, Yonemori F, Wakitani K. Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound. Eur J Pharmacol 1999; 371: 51-58.
14. 2+ influx by phosphodiesterase inhibition. Br J Pharmacol 2000; 129: 901-908.
15. Ido Y, Mchowat J, Chang KC et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994; 43: 1469-1477.
16. Miyoshi T, Goto I. Serial in vivo determinations of nerve conduction velocity in rat tails: physiological and pathological changes. Electroencephalogr Clin Neurophysiol 1973; 35: 125-131.
17. Spüler M, Dimpfel W, Tüller HU. Effect of gangliosides on nerve conduction velocity during diabetic neuropathy in the rat. Arch Int Pharmacodyn Ther 1987; 287: 211-223.
18. Tadokoro S, Kuribara H, Shirasaka K. Fully automatic measurement of behavioral rhythms in rats and applications. Jpn J Neuropsychopharmacol 1981; 3: 785-803.
19. Portha B, Blondel O, Serradas P. The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabetes Metab 1989; 15: 61-75.
20. Giroix MH, Portha B, Kergoat M. Glucose insensitivity and amino-acid hypersensitivity of insulin release in rats with non-insulin-dependent diabetes. Diabetes 1983; 32: 445-451.
21. Giroix MH, Rasschaert J, Sener A. Study of hexose transport, glycerol phosphate shuttle and Krebs cycle in islets of adult rats injected with streptozotocin during the neonatal. Mol Cell Endocrinol 1992; 83: 95-104.
22. Mozaffari MS, Warren BK, Russell CM. Renal function in the noninsulin-dependent diabetic rat: effects of unilateral nephrectomy. J Pharmacol Toxicol Methods 1997; 37: 197-203.
23. Chen YN, Chen SY, Zeng LJ et al. Secondary sulphonylurea failure: what pathogenesis is responsible? Br J Biomed Sci 2003; 60 (1): 9-13.
24. Dunber JC, Foà PP. An inhibitory effect of tolbutamide and glibenclamide on the pancreatic islets of normal animals. Diabetologia 1974; 10: 27-35.
25. Weber JW, Colombo JP, Goldberg RI et al. Pancreatic function in alloxan "Subdiabetic" rats long-term treated with tolbutamide. Diabetes 1961; 10 (2): 122-129.
26. Filipponi P, Marcelli M, Nicoletti I et al. Suppressive effect of long term sulfonylurea treatment on A, B, and D cells of normal rat pancreas. Endocrinology 1983; 113: 1972-1979.
27. Giroix MH, Baetens D, Rasschaert J. Enzymic and metabolic anomalies in islets of diabetic rats: relationship to B cell mass. Endocrinology 1992; 130: 2634-2640.
28. Robertson RP, Harmon J, Tran PO. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
29. Östenson CG, Fiere V, Ahmed M. Decreased cortical bone thickness in spontaneously non-insulin-dependent diabetic GK rats. J Diabetes Complications 1997; 11: 319-322.
30. Goto Y, Kakizaki M, Yagihashi S. Neurological findings in spontaneously diabetic rats. Excepta Med Int Cong Ser 1982; 581: 26-38.
31. Shibata T, Takeuchi S, Yokota S et al. Effect of peroxisome proliferator-activated receptor-α and γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000; 130: 494-504.
32. Iwase M, Nunoi K, Sadashima S, Kikuchi M, Fujishima M. Liver, kidney and islet cell tumors in spontaneously hypertensive and normotensive rats treated neonatally with streptozotocin. Tohoku J Exp Med 1989; 159 (2): 83-90.